Abstract
Aim, patients & methods: To evaluate the real-world setting use of sunitinib, we reviewed data of our patients from January 2007 to December 2014. Results: In 114 patients, sunitinib was used as first-line TKI. Out of 110 evaluable patients, 5 complete responses, 37 partial responses, 42 stabilizations were reported. Median progression-free survival and overall survival (OS) were 14.3 and 28.4 months. Patients who received ≥4 full-dose cycles had a better OS (p = 0.02). A neutrophil-lymphocyte ratio
Original language | English |
---|---|
Pages (from-to) | 909-919 |
Number of pages | 11 |
Journal | Future Oncology |
Volume | 12 |
Issue number | 7 |
DOIs | |
Publication status | Published - Apr 1 2016 |
Keywords
- dose exposure
- neutrophil-lymphocite ratio
- real world
- renal cell carcinoma
- sunitinib
- survival
ASJC Scopus subject areas
- Oncology
- Cancer Research